[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100630948":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":25,"centralContacts":30,"locations":36,"responsibleParty":416,"collaborators":25,"id":418,"slug":419,"hasResults":420,"nctId":421,"briefTitle":422,"officialTitle":423,"acronym":424,"eligibilityCriteria":425,"healthyVolunteers":420,"sex":426,"minAge":427,"maxAge":428,"enrollmentInfo":429,"targetDuration":25,"studyType":432,"phases":433,"briefSummary":435,"conditions":436,"keywords":438,"overallStatus":39,"whyStopped":25,"lastUpdateSubmitDate":441,"lastUpdatePostDateStruct":442,"startDateStruct":445,"completionDateStruct":447,"leadSponsor":449,"locationsCount":450},{"fullName":5,"class":6},"LB Pharmaceuticals Inc.","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"LB-102","ACTIVE_COMPARATOR","Patients will be randomized 1:1 to either active drug (LB-102) or Placebo. Dosing of LB-102 will start at 25 mg QD fixed dose for the first 3 weeks. At the start of Week 4, the dose of LB-102 may be increased to 50 mg QD based on the Clinical Global Impression Scale, Bipolar Version (CGI BP) improvement score.",[13],"Drug: LB-102",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","Patients will be randomized 1:1 to either LB-102 or placebo. Those patients on placebo will take one table QD for the length (6 weeks) of the clinical study. Patients will receive a new bottle of medication each week. Patients and PI, study staff will be blinded to which treatment (LB-102 or placebo), patients are randomized to.\n\nPatients will restart antidepressant or mood stabilizer treatment (if applicable) after the last dose of the study treatment on study day 43",[19],"Other: Placebo",[21,26],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","N-methyl amisulpride",[9],null,{"type":27,"name":15,"description":28,"armGroupLabels":29,"otherNames":25},"OTHER","Inactive substance that looks identical to the active treatment",[15],[31],{"name":32,"role":33,"phone":34,"phoneExt":25,"email":35},"George Nomikos","CONTACT","(212) 605-0300","clinicaltrials@lbpharma.us",[37,59,72,88,103,116,130,144,154,165,177,191,208,227,241,256,272,286,301,316,331,345,360,375,389,401],{"facility":38,"status":39,"city":40,"state":41,"zip":42,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"Pillar Clinical Research","RECRUITING","Bentonville","Arkansas","72712","United States","US",{"type":46,"coordinates":47},"Point",[48,49],-94.20882,36.37285,{"lat":49,"lon":48},[52,55],{"name":53,"role":33,"phone":25,"phoneExt":25,"email":54},"Fayz Hudefi, MD","studies@pillarhc.com",{"name":56,"role":33,"phone":57,"phoneExt":25,"email":58},"Nicole Gutierrez","479-367-2688","ngutierrez@pillarhc.com",{"facility":38,"status":39,"city":60,"state":41,"zip":61,"country":43,"countryCode":44,"cosmosGeoPoint":62,"geoPoint":66,"contacts":67},"Little Rock","72204",{"type":46,"coordinates":63},[64,65],-92.28959,34.74648,{"lat":65,"lon":64},[68,70],{"name":69,"role":33,"phone":25,"phoneExt":25,"email":54},"Leslie Smith, MD",{"name":56,"role":33,"phone":71,"phoneExt":25,"email":58},"501-307-1919",{"facility":73,"status":39,"city":74,"state":75,"zip":76,"country":43,"countryCode":44,"cosmosGeoPoint":77,"geoPoint":81,"contacts":82},"CenExel","Bellflower","California","90706",{"type":46,"coordinates":78},[79,80],-118.11701,33.88168,{"lat":80,"lon":79},[83],{"name":84,"role":33,"phone":85,"phoneExt":86,"email":87},"Maria Nunez Perez","866-478-8391","1319","m.nunezperez@cenexel.com",{"facility":89,"status":39,"city":90,"state":75,"zip":91,"country":43,"countryCode":44,"cosmosGeoPoint":92,"geoPoint":96,"contacts":97},"ProScience Research Group","Culver City","90230",{"type":46,"coordinates":93},[94,95],-118.39647,34.02112,{"lat":95,"lon":94},[98],{"name":99,"role":33,"phone":100,"phoneExt":101,"email":102},"Paola Aguirre","424-227-8127","2","paola.aguirre@proscienceerg.com",{"facility":73,"status":39,"city":104,"state":75,"zip":105,"country":43,"countryCode":44,"cosmosGeoPoint":106,"geoPoint":110,"contacts":111},"Garden Grove","922845",{"type":46,"coordinates":107},[108,109],-117.94145,33.77391,{"lat":109,"lon":108},[112],{"name":113,"role":33,"phone":114,"phoneExt":25,"email":115},"Dakota Gainers","714-943-5874","d.gainers@cenexel.com",{"facility":117,"status":39,"city":118,"state":75,"zip":119,"country":43,"countryCode":44,"cosmosGeoPoint":120,"geoPoint":124,"contacts":125},"Synergy San Diego","Lemon Grove","91945",{"type":46,"coordinates":121},[122,123],-117.03142,32.74255,{"lat":123,"lon":122},[126],{"name":127,"role":33,"phone":128,"phoneExt":25,"email":129},"Corey Weise","619-303-6130","cweise@ergclinical.com",{"facility":131,"status":39,"city":132,"state":75,"zip":133,"country":43,"countryCode":44,"cosmosGeoPoint":134,"geoPoint":138,"contacts":139},"NRC Research Institute","Los Angeles","90015",{"type":46,"coordinates":135},[136,137],-118.24368,34.05223,{"lat":137,"lon":136},[140],{"name":141,"role":33,"phone":142,"phoneExt":25,"email":143},"Abigail Parera","213-992-9216","aparera@nrcresearch.com",{"facility":131,"status":39,"city":145,"state":75,"zip":146,"country":43,"countryCode":44,"cosmosGeoPoint":147,"geoPoint":151,"contacts":152},"Orange","92868",{"type":46,"coordinates":148},[149,150],-117.85311,33.78779,{"lat":150,"lon":149},[153],{"name":141,"role":33,"phone":114,"phoneExt":25,"email":143},{"facility":73,"status":39,"city":155,"state":75,"zip":156,"country":43,"countryCode":44,"cosmosGeoPoint":157,"geoPoint":161,"contacts":162},"Riverside","92506",{"type":46,"coordinates":158},[159,160],-117.39616,33.95335,{"lat":160,"lon":159},[163],{"name":84,"role":33,"phone":164,"phoneExt":25,"email":87},"866-478-2688",{"facility":73,"status":39,"city":166,"state":75,"zip":167,"country":43,"countryCode":44,"cosmosGeoPoint":168,"geoPoint":172,"contacts":173},"Torrance","90504",{"type":46,"coordinates":169},[170,171],-118.34063,33.83585,{"lat":171,"lon":170},[174],{"name":25,"role":33,"phone":175,"phoneExt":25,"email":176},"844-424-9494","ns.outreach@cenexel.com",{"facility":178,"status":39,"city":179,"state":180,"zip":181,"country":43,"countryCode":44,"cosmosGeoPoint":182,"geoPoint":186,"contacts":187},"St. Jude Clinical Research","Doral","Florida","33172",{"type":46,"coordinates":183},[184,185],-80.35533,25.81954,{"lat":185,"lon":184},[188],{"name":25,"role":33,"phone":189,"phoneExt":25,"email":190},"305-507-2273","slinares@stjudeclinicalresearch.com",{"facility":192,"status":39,"city":193,"state":180,"zip":194,"country":43,"countryCode":44,"cosmosGeoPoint":195,"geoPoint":199,"contacts":200},"Cenexel Hollywood Florida","Hollywood","33019",{"type":46,"coordinates":196},[197,198],-80.14949,26.0112,{"lat":198,"lon":197},[201,205],{"name":202,"role":33,"phone":203,"phoneExt":25,"email":204},"Edwin Gomez, MD","954-990-7649","e.gomez@cenexel.com",{"name":206,"role":33,"phone":203,"phoneExt":25,"email":207},"Ana Molero","Al.molero@cenexel.com",{"facility":209,"status":39,"city":210,"state":180,"zip":211,"country":43,"countryCode":44,"cosmosGeoPoint":212,"geoPoint":216,"contacts":217},"Innovative Clinical Research","Miami Lakes","33016",{"type":46,"coordinates":213},[214,215],-80.30866,25.90871,{"lat":215,"lon":214},[218,223],{"name":219,"role":33,"phone":220,"phoneExt":221,"email":222},"Melissa Rodco","305-722-8444","6006","mrodco@segaltrials.com",{"name":224,"role":33,"phone":220,"phoneExt":225,"email":226},"Luis Sotolongo","3611","lsotolongo@segaltrials.com",{"facility":228,"status":39,"city":229,"state":180,"zip":230,"country":43,"countryCode":44,"cosmosGeoPoint":231,"geoPoint":235,"contacts":236},"Health Synergy Clinical Research","West Palm Beach","33407",{"type":46,"coordinates":232},[233,234],-80.05337,26.71534,{"lat":234,"lon":233},[237],{"name":238,"role":33,"phone":239,"phoneExt":25,"email":240},"Katherine Grigelis","561-473-3472","kat@hscresearch.com",{"facility":242,"status":39,"city":243,"state":244,"zip":245,"country":43,"countryCode":44,"cosmosGeoPoint":246,"geoPoint":250,"contacts":251},"Trialmed","Atlanta","Georgia","30328",{"type":46,"coordinates":247},[248,249],-84.38798,33.749,{"lat":249,"lon":248},[252],{"name":253,"role":33,"phone":254,"phoneExt":25,"email":255},"Jennifer Flemming","678-559-1119","jennifer.flemming@trialmed.com",{"facility":257,"status":39,"city":258,"state":244,"zip":259,"country":43,"countryCode":44,"cosmosGeoPoint":260,"geoPoint":264,"contacts":265},"Cenexel Decatur GA","Decatur","30030",{"type":46,"coordinates":261},[262,263],-84.29631,33.77483,{"lat":263,"lon":262},[266,270],{"name":267,"role":33,"phone":268,"phoneExt":25,"email":269},"Katherine Prowse","404-537-1281","k.prowse@cenexel.com",{"name":25,"role":33,"phone":25,"phoneExt":25,"email":271},"m.mahathre@cenexel.com",{"facility":38,"status":39,"city":273,"state":274,"zip":275,"country":43,"countryCode":44,"cosmosGeoPoint":276,"geoPoint":280,"contacts":281},"Chicago","Illinois","60641",{"type":46,"coordinates":277},[278,279],-87.65005,41.85003,{"lat":279,"lon":278},[282,285],{"name":283,"role":33,"phone":284,"phoneExt":25,"email":54},"Roueen Rafeyan, MD","224-534-7332",{"name":56,"role":33,"phone":57,"phoneExt":25,"email":58},{"facility":287,"status":39,"city":288,"state":289,"zip":290,"country":43,"countryCode":44,"cosmosGeoPoint":291,"geoPoint":295,"contacts":296},"NSRT","Detroit","Michigan","48203",{"type":46,"coordinates":292},[293,294],-83.04575,42.33143,{"lat":294,"lon":293},[297],{"name":298,"role":33,"phone":299,"phoneExt":25,"email":300},"Tricia Harrison","248-575-1268","tricia@qcrnetwork.com",{"facility":302,"status":39,"city":303,"state":304,"zip":305,"country":43,"countryCode":44,"cosmosGeoPoint":306,"geoPoint":310,"contacts":311},"Arch Clinical Trials","St Louis","Missouri","63141",{"type":46,"coordinates":307},[308,309],-90.19789,38.62727,{"lat":309,"lon":308},[312],{"name":313,"role":33,"phone":314,"phoneExt":25,"email":315},"Israa Diab","314-266-1243","idiab@archclinicaltrials.com",{"facility":317,"status":39,"city":318,"state":319,"zip":320,"country":43,"countryCode":44,"cosmosGeoPoint":321,"geoPoint":325,"contacts":326},"Redbird Research","Las Vegas","Nevada","89119",{"type":46,"coordinates":322},[323,324],-115.13722,36.17497,{"lat":324,"lon":323},[327],{"name":328,"role":33,"phone":329,"phoneExt":25,"email":330},"Haley Lefever","702-577-2000","info@redbird-research.com",{"facility":332,"status":39,"city":333,"state":333,"zip":334,"country":43,"countryCode":44,"cosmosGeoPoint":335,"geoPoint":339,"contacts":340},"Manhattan Behavioral Medicine","New York","10036",{"type":46,"coordinates":336},[337,338],-74.00597,40.71427,{"lat":338,"lon":337},[341],{"name":342,"role":33,"phone":343,"phoneExt":25,"email":344},"Judith Joseph, MD","646-678-4073","joseph@nymbm.com",{"facility":346,"status":39,"city":347,"state":348,"zip":349,"country":43,"countryCode":44,"cosmosGeoPoint":350,"geoPoint":354,"contacts":355},"Neuro-Behavioral Clinical Research","Canton","Ohio","44720",{"type":46,"coordinates":351},[352,353],-81.37845,40.79895,{"lat":353,"lon":352},[356],{"name":357,"role":33,"phone":358,"phoneExt":25,"email":359},"Crystal Blackford","330-493-1118","cblackford@nb-cr.com",{"facility":361,"status":39,"city":362,"state":363,"zip":364,"country":43,"countryCode":44,"cosmosGeoPoint":365,"geoPoint":369,"contacts":370},"Adams Clinical","Philadelphia","Pennsylvania","19104",{"type":46,"coordinates":366},[367,368],-75.16362,39.95238,{"lat":368,"lon":367},[371],{"name":372,"role":33,"phone":373,"phoneExt":25,"email":374},"Isabel Bear","267-207-2511","ibear@adamsclinical.com",{"facility":361,"status":39,"city":376,"state":377,"zip":378,"country":43,"countryCode":44,"cosmosGeoPoint":379,"geoPoint":383,"contacts":384},"DeSoto","Texas","75115",{"type":46,"coordinates":380},[381,382],-96.85695,32.58986,{"lat":382,"lon":381},[385],{"name":386,"role":33,"phone":387,"phoneExt":25,"email":388},"Jaya Koonjbearry","972-283-6286","info@adamsclinical.com",{"facility":38,"status":39,"city":390,"state":377,"zip":391,"country":43,"countryCode":44,"cosmosGeoPoint":392,"geoPoint":396,"contacts":397},"Richardson","75080",{"type":46,"coordinates":393},[394,395],-96.72972,32.94818,{"lat":395,"lon":394},[398],{"name":399,"role":33,"phone":400,"phoneExt":25,"email":54},"Scott Barley, MD","214-396-4844",{"facility":402,"status":39,"city":403,"state":404,"zip":405,"country":43,"countryCode":44,"cosmosGeoPoint":406,"geoPoint":410,"contacts":411},"Northwest Clinical Research Center","Bellevue","Washington","98007",{"type":46,"coordinates":407},[408,409],-122.20068,47.61038,{"lat":409,"lon":408},[412],{"name":413,"role":33,"phone":414,"phoneExt":25,"email":415},"Kimberlee Wheeler","425-453-0404","kwheeler@nwcrc.net",{"type":417,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100630948","phase-2-multicenter-study-to-assess-the-efficacy-and-safety-of-lb-102-in-the-treatment-of-adult-patients-with-bp1mde-100630948",false,"NCT07494305","Multicenter Study to Assess the Efficacy and Safety of LB-102 in the Treatment of Adult Patients With BP1MDE.","A Randomized, Double Blind, Placebo Controlled, Multicenter Study to Assess the Efficacy and Safety of LB-102 in the Treatment of Adult Patients With Major Depressive Episodes Associated With Bipolar I Disorder","Illuminate1","Inclusion Criteria:\n\n* Sign IRB approved ICF, Stable living environment\n* Diagnosis of Bipolar1 disorder defined by criteria in the DSM 5 and currently experiencing a MDE without psychotic or mixed features, and supported by the SCID 5 CT\n* Currently experiencing an MDE that began at least 4 weeks but no more than 18 months prior to randomization\n* Currently treated in an out-patient environment\n* MADRS 10 total score ≥24 at both Screening and Baseline with a difference of \\\u003C20% in scores between visits.\n* Clinical Global Impression Scale, Bipolar Version Severity of Illness scale (CGI BP S) depression score ≥4 at both Screening and Baseline.\n* YMRS total score ≤12 at both Screening and Baseline.\n* Good physical health\n* BMI of ≥18 and ≤40 kg\u002Fm2.\n* Eligibility confirmed centrally for the severity, diagnosis, and treatment history by the SAFER interview.\n\nExclusion Criteria:\n\n* Sexually active woman of childbearing potential and male who are not practicing 2 different methods of birth control or woman who is currently breast feeding\n* History of non-response to 2 adequate medication trials for depressive symptoms\n* Improvement of ≥20% in MADRS 10 total score between the screening and baseline assessments\n* Have bipolar disorder with mixed features or considered as rapid cyclers\n* Plan to initiate formal cognitive or behavioral therapy, systematic psychotherapy during the study, or plan to initiate such therapy during the study\n* History of disorders other than bipolar disorder, confirmed by previous psychiatric evaluation or the DSM 5 within 12 months prior to Screening\n* Experience of hallucinations, delusions, or any other psychotic symptomatology in the current MDE attributable to a primary DSM 5 diagnosis other than bipolar disorder.\n* Hospitalized for mania associated with Bipolar I Disorder within 30 days prior to Screening. Any previous manic phase must have completely resolved before enrollment in the study.\n* Significant risk for suicidal behavior during the study as determined by the Investigator's clinical assessment\n* Hypo or hyperthyroidism\n* Insulin dependent diabetes\n* Uncontrolled hypertension\n* Known significant cardiac disease\n* Laboratory results outside the defined protocol ranges\n* Clinically significant abnormal ECG findings\n* Received electroconvulsive therapy (ECT) within 90 days prior to Screening.\n* Received Transcranial Magnetic Stimulation within 90 days prior to Screening\n* Currently taking prohibited medications as defined in the protocol\n* History of non-response and\u002For responded only to ketamine, ECT or vagus nerve stimulation\n* Received GLP-1 within 30 of screening\n* History of organ disease that in the opinion of the PI would not make the patient eligible for participation","ALL","18 Years","65 Years",{"count":430,"type":431},320,"ESTIMATED","INTERVENTIONAL",[434],"PHASE2","Phase II study for patients with Bipolar 1 Disorder experiencing major depressive episode. Patient eligible for enrollment will be randomized (like flipping a coin) to either active drug (LB-102 or placebo). Treatment is for 6 weeks.",[437],"Bipolar I Disorder",[439,440],"Bipolar","Major depression episode","2026-07-24",{"date":443,"type":444},"2026-07-27","ACTUAL",{"date":446,"type":444},"2026-01-23",{"date":448,"type":431},"2028-02",{"name":5,"class":6},26]